Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Elite Pharmaceuticals Inc ELTP

Healthcare
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. The Company specializes in developing and manufacturing oral, controlled-release drug products. It owns multiple generic products which has been licensed to Prasco, LLC and TAGI Pharma. The Company’s segments include Abbreviated New Drug Applications (ANDA) and New Drug... see more

Recent & Breaking News (OTCQB:ELTP)

Elite Pharmaceuticals Receives FDA Approval for Generic Vyvanse

Newsfile 10 days ago

Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 and Provides Conference Call Information

Newsfile 13 days ago

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2025 Financial Results on November 15, 2024

Newsfile November 7, 2024

Elite Pharmaceuticals' Generic Adderall(R) Receives Marketing Approval from the Israeli Ministry of Health

Newsfile October 10, 2024

Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Codeine Phosphate Tablets

Newsfile October 7, 2024

Elite Pharmaceuticals Announces Commercial Launch of Generic Methotrexate Sodium

Newsfile August 27, 2024

Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2025 Ended June 30, 2024 and Provides Conference Call Information

Newsfile August 14, 2024

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2025 Financial Results on August 15, 2024

Newsfile August 9, 2024

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Conference Call Information

Newsfile July 1, 2024

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2024 Financial Results on July 2, 2024

Newsfile June 26, 2024

Elite Pharmaceuticals Receives FDA Approval for Generic Methotrexate

Accesswire May 20, 2024

Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information

Accesswire February 14, 2024

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2024 Financial Results on February 15, 2024

Accesswire February 8, 2024

Elite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System Stimulant

Accesswire December 26, 2023

Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR(R) to Marketing Partner Prasco, LLC

Accesswire December 12, 2023

Elite Pharmaceuticals, Inc. Reports Financial Results for Second Quarter of Fiscal Year 2024 ended September 30, 2023 and Provides Conference Call Information

Accesswire November 14, 2023

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2024 Financial Results on November 15, 2023

Accesswire November 10, 2023

Elite Pharmaceuticals Files ANDA with US FDA to Market Opiate Analgesic Product

Accesswire September 25, 2023

Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial Officer

Accesswire September 7, 2023

Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study

Accesswire August 28, 2023